Abstract: An electrochemical device having an operational voltage up to 4.5 V in combination with a high concentration of an electrolyte salt consisting of a tetrafluoroborate salt and a eutectic of two solvents in which ethylene carbonate is one and an improved carbon electrode a preferred electrochemical device is a capacitor.

Abstract: Carbon electrodes for a capacitor having conditioned carbon elements in combination with a high concentration of an electrolyte tetrafluoroborate salt and a non-aqueous aprotic solvent to provide an operational voltage up to 4.5V and capacitors used with the carbon electrodes.

Abstract: There is provided a process for preparing lithium cobaltate and to lithium-containing cobalt oxides which is used in lithium battery cathodes. Also, there is provided cathodes for lithium batteries.

Abstract: The present invention provides a process for preparing lithium manganate having lithium-in cell stability by utilizing manganese oxides having lower oxidation states in the furnacing step and by using stoichiometric amounts of lithium hydroxide monohydrate and a manganese oxide in water as a starting mixture. Cr, Ni, Mg, AL oxides are optionally added.

Abstract: Peptide and pseudopeptide derivatives of the formula: ##STR1## wherein R.sup.1 and R.sup.2 stand for defined hydrocarbyl or halo-hydrocarbyl substituents, for example alk-2-enyl radicals; .dbd.N--A-- stands for a defined amino acid residue; B, D and E, which may be the same or different, stand for a valency bond or a defined amino acid residue; F stands for a defined amino acid residue; X stands for a carboxy, ester or amide group; and the linkages between the amino acid residues are peptide linkages or at least one of said linkages is a defined pseudo linkage; and pharmaceutically-acceptable salts thereof. Processes for the manufacture of the compounds. Pharmaceutical compositions comprising one of the compounds and a pharmaceutical diluent or carrier. The compounds are antagonists at the opiate receptors, and most of them are selective .delta.-receptor antagonists.

Abstract: The disclosure relates to novel polypeptides which possess analgesic activity, to processes for their manufacture and to pharmaceutical compositions containing them.

Abstract: The disclosure relates to novel polypeptides which possess analgesic and sedative activity, to processes for their manufacture and to compositions containing them. Typical of the peptides disclosed isH-Tyr-D-Ala-Gly-Phe-Leu-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-OH.